These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 819576)
41. [Results of a study of the safety, reactogenicity and immunologic effectiveness of pyoimmunogen in the immunization of volunteer donors]. Krokhina MA; Grishina IA; Arkhipova NA; Zarubina EK; Edvabnaia LS Zh Mikrobiol Epidemiol Immunobiol; 1981 Oct; (10):95-8. PubMed ID: 7331614 [TBL] [Abstract][Full Text] [Related]
42. Pseudomonas aeruginosa: prevention better than cure? Mellor JA; Miler JJ Dev Biol Stand; 1979; 43():53-9. PubMed ID: 118071 [TBL] [Abstract][Full Text] [Related]
43. OprF/I-vaccinated sera inhibit binding of human interferon-gamma to Pseudomonas aeruginosa. Ding B; von Specht BU; Li Y Vaccine; 2010 Jun; 28(25):4119-22. PubMed ID: 20433804 [TBL] [Abstract][Full Text] [Related]
44. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa. Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788 [TBL] [Abstract][Full Text] [Related]
45. Systematic utilization of an antipseudomonas aeruginosa vaccine in a severe burn unit. Wassermann D; Schlotterer M; Paul P; Rieu M Scand J Plast Reconstr Surg; 1979; 13(1):81-4. PubMed ID: 451484 [TBL] [Abstract][Full Text] [Related]
46. [Study on Construction of Recombinant Bb-pGEX- Liu X; Li WG; Luo GX Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):13-17. PubMed ID: 29737082 [TBL] [Abstract][Full Text] [Related]
47. An acellular vaccine from Pseudomonas aeruginosa: homologous and crossed protection between serogroups according to Habs' classification. Berche P; Véron M; Fermanian J; Daoulas-Lebourdelles F; Guégen A Ann Microbiol (Paris); 1979; 130(2):179-88. PubMed ID: 90473 [TBL] [Abstract][Full Text] [Related]
48. Safety and immunogenicity of subcutaneous or intramuscular administration of a monovalent inactivated vaccine against Leptospira interrogans serogroup Icterohaemorrhagiae in healthy volunteers. Laurichesse H; Gourdon F; Smits HL; Abdoe TH; Estavoyer JM; Rebika H; Pouliquen P; Catalina P; Dubray C; Beytout J Clin Microbiol Infect; 2007 Apr; 13(4):395-403. PubMed ID: 17359323 [TBL] [Abstract][Full Text] [Related]
50. Field studies: pseudomonas pneumonia of mink. Long GG; Gorham JR Am J Vet Res; 1981 Dec; 42(12):2129-33. PubMed ID: 6803621 [TBL] [Abstract][Full Text] [Related]
54. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. Cryz SJ; Fürer E; Cross AS; Wegmann A; Germanier R; Sadoff JC J Clin Invest; 1987 Jul; 80(1):51-6. PubMed ID: 3110215 [TBL] [Abstract][Full Text] [Related]
55. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization. Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420 [TBL] [Abstract][Full Text] [Related]
56. The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia. Naito Y; Hamaoka S; Kinoshita M; Kainuma A; Shimizu M; Katoh H; Moriyama K; Ishii KJ; Sawa T Microbiol Immunol; 2018 Dec; 62(12):774-785. PubMed ID: 30378708 [TBL] [Abstract][Full Text] [Related]
57. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100 [TBL] [Abstract][Full Text] [Related]
58. Obtention and assay of rabbit anti-Pseudomonas serum. Laborde HF; Legnani de Fajardo C J Bacteriol; 1969 Jun; 98(3):992-5. PubMed ID: 4182531 [TBL] [Abstract][Full Text] [Related]
59. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231 [TBL] [Abstract][Full Text] [Related]
60. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa. Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]